VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 25, 2007) - enGene, Inc., a privately held biotechnology company developing an innovative approach for the long-term treatment of diabetes called GEMS™-Insulin, announced today that two scientific co-founders will be presenting new data on the company’s core technology:
